Immune therapeutic targeting of glioma cancer stem cells

Mustafa Aziz Hatiboglu, Jun Wei, Adam Sauh Gee Wu, Amy B. Heimberger

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.

Original languageEnglish (US)
Pages (from-to)217-227
Number of pages11
JournalTargeted Oncology
Issue number3
StatePublished - Sep 2010
Externally publishedYes


  • Glioblastoma multiforme
  • Glioma cancer stem cells
  • Immunotherapy
  • STAT3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Immune therapeutic targeting of glioma cancer stem cells'. Together they form a unique fingerprint.

Cite this